Fine Needle-Diathermy Regresses Pathological Corneal (Lymph)Angiogenesis and Promotes High-Risk Corneal Transplant Survival

[1]  J. Horstmann,et al.  Novel Method to Detect Corneal Lymphatic Vessels In Vivo by Intrastromal Injection of Fluorescein , 2017, Cornea.

[2]  J. Horstmann,et al.  Label-Free In Vivo Imaging of Corneal Lymphatic Vessels Using Microscopic Optical Coherence Tomography. , 2017, Investigative ophthalmology & visual science.

[3]  R. Hussain,et al.  Fine-Needle Diathermy with Simultaneous Subconjunctival Bevacizumab , 2017, Seminars in ophthalmology.

[4]  C. Cursiefen,et al.  IL-10 Indirectly Regulates Corneal Lymphangiogenesis and Resolution of Inflammation via Macrophages. , 2016, The American journal of pathology.

[5]  K. Mireskandari,et al.  Corneal Fine Needle Diathermy With Adjuvant Bevacizumab to Treat Corneal Neovascularization in Children , 2015, Cornea.

[6]  Yalin Zheng,et al.  Corneal angiography for guiding and evaluating fine-needle diathermy treatment of corneal neovascularization. , 2015, Ophthalmology.

[7]  D. Meller,et al.  Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I-CAN study. , 2014, Ophthalmology.

[8]  N. Lagali,et al.  Early effects of dexamethasone and anti-VEGF therapy in an inflammatory corneal neovascularization model. , 2014, Experimental eye research.

[9]  D. Anderson,et al.  Long-term outcomes of Fine Needle Diathermy for established corneal neovascularisation , 2014, British Journal of Ophthalmology.

[10]  H. Dua,et al.  Fine needle diathermy occlusion of corneal vessels , 2014, British Journal of Ophthalmology.

[11]  Jin A. Choi,et al.  Presurgical Corticosteroid Treatment Improves Corneal Transplant Survival in Mice , 2013, Cornea.

[12]  K. Tsubota,et al.  Keratoplasty Postoperative Treatment Update , 2013, Cornea.

[13]  K. Maruyama,et al.  Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases , 2013, Progress in Retinal and Eye Research.

[14]  D. Azar,et al.  Corneal neovascularization: an anti-VEGF therapy review. , 2012, Survey of ophthalmology.

[15]  F. Kruse,et al.  Angioregressive Pretreatment of Mature Corneal Blood Vessels Before Keratoplasty: Fine-Needle Vessel Coagulation Combined With Anti-VEGFs , 2012, Cornea.

[16]  D. Saban,et al.  Suppression of inflammatory corneal lymphangiogenesis by application of topical corticosteroids. , 2011, Archives of ophthalmology.

[17]  S. Thatte.  Fine needle diathermy - a choice for managing corneal vascularization. , 2011, Nepalese journal of ophthalmology : a biannual peer-reviewed academic journal of the Nepal Ophthalmic Society : NEPJOPH.

[18]  Claus Cursiefen,et al.  Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis. , 2010, Ophthalmology.

[19]  S. Wiegand,et al.  Cutting Edge: Lymphatic Vessels, Not Blood Vessels, Primarily Mediate Immune Rejections After Transplantation , 2009, The Journal of Immunology.

[20]  F. Horn,et al.  GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial. , 2009, Ophthalmology.

[21]  Claus Cursiefen,et al.  Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin®) eye drops against corneal neovascularization , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.

[22]  F. Horn,et al.  Improved semiautomatic method for morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts. , 2008, Experimental eye research.

[23]  M. Dana,et al.  Graft failure IV. Immunologic mechanisms of corneal transplant rejection , 2008, International Ophthalmology.

[24]  Björn Bachmann,et al.  Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. , 2007, Investigative ophthalmology & visual science.

[25]  R. Dana,et al.  Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[26]  K. Maruyama,et al.  Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. , 2004, Investigative ophthalmology & visual science.

[27]  Jingtai Cao,et al.  VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. , 2004, The Journal of clinical investigation.

[28]  J. Streilein.  Ocular immune privilege: therapeutic opportunities from an experiment of nature , 2003, Nature Reviews Immunology.

[29]  U. Schlötzer-Schrehardt,et al.  Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation , 2003, The British journal of ophthalmology.

[30]  K. Alitalo,et al.  Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin. , 2002, Investigative ophthalmology & visual science.

[31]  B. Seitz,et al.  Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty study , 2002, Graefe's Archive for Clinical and Experimental Ophthalmology.

[32]  D. Azar,et al.  Corneal neovascularization. , 2001, Current opinion in ophthalmology.

[33]  M. Dana,et al.  Anterior chamber-associated immune deviation, ocular immune privilege, and orthotopic corneal allografts. , 1999, Transplantation proceedings.

[34]  A. Adamis,et al.  Ocular neovascularization: an epidemiologic review. , 1998, Survey of ophthalmology.

[35]  J. Streilein,et al.  Immunosuppressive properties of tissues obtained from eyes with experimentally manipulated corneas. , 1996, Investigative ophthalmology & visual science.

[36]  B. Ksander,et al.  Fate of orthotopic corneal allografts in eyes that cannot support anterior chamber-associated immune deviation induction. , 1995, Investigative ophthalmology & visual science.

[37]  J. Streilein,et al.  ORTHOTOPIC CORNEAL TRANSPLANTATION IN MICE—EVIDENCE THAT THE IMMUNOGENETIC RULES OF REJECTION DO NOT APPLY , 1992, Transplantation.

[38]  C. Foster,et al.  Corneal laser photocoagulation for treatment of neovascularization. Efficacy of 577 nm yellow dye laser. , 1992, Ophthalmology.

[39]  D. Harris,et al.  Photodynamic Therapy for Corneal Neovascularization , 1991, Cornea.

[40]  S. Tseng,et al.  Induction of conjunctival transdifferentiation on vascularized corneas by photothrombotic occlusion of corneal neovascularization. , 1988, Ophthalmology.

[41]  Neovascularisation. , 1986, The British journal of ophthalmology.

[42]  R J Marsh,et al.  Treatment of lipid keratopathy with the argon laser. , 1982, The British journal of ophthalmology.

[43]  A. Garner,et al.  Corneal neovascularization treated with argon laser. , 1976, British Journal of Ophthalmology.

[44]  N. Ashton,et al.  Effect of Cortisone on Vascularization and Opacification of the Cornea Induced by Alloxan , 1951, The British journal of ophthalmology.